AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NeoGenomics (NASDAQ:NEO) reported Q3 sales of $187.8 million, up 11.9% YoY, beating analysts' estimates. The company's non-GAAP profit of $0.03 per share was in line with estimates. NeoGenomics reconfirmed its full-year revenue guidance of $723 million and reiterated its adjusted EPS guidance of $0.10.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet